Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model

BMC Cardiovascular Disorders

Volumn 10, Issue , 2010, Pages

  van der Pals, Jesper ^a   Koul, Sasha ^a   Andersson, Patrik ^a   Götberg, Matthias ^a   Ubachs, Joey F A ^a   Kanski, Mikael ^a   Arheden, Håkan ^a   Olivecrona, Göran K ^a   Larsson, Bengt ^a,b   Erlinge, David ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Alligator Bioscience AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADC 1004; COMPLEMENT COMPONENT C5A RECEPTOR; TROPONIN T; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; CHEMOTAXIS INHIBITORY PROTEIN, STAPHYLOCOCCUS AUREUS; MUTANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GAS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; EXPERIMENTAL PIG; FEMALE; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART OUTPUT; HEART PROTECTION; HEART RATE; ISCHEMIA; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REPERFUSION INJURY; TREATMENT RESPONSE; ANGIOPLASTY; ANIMAL; CLINICAL PROTOCOL; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEART; HEART MUSCLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; SWINE;

ANGIOPLASTY; ANIMALS; BACTERIAL PROTEINS; CLINICAL PROTOCOLS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; HEART; HUMANS; INJECTIONS, INTRAVENOUS; MUTANT PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIUM; RECEPTOR, ANAPHYLATOXIN C5A; REPERFUSION INJURY; SWINE;

EID: 77957104721     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-10-45     Document Type: Article

References (48)

1. Kloner RA. Does reperfusion injury exist in humans?. J Am Coll Cardiol 1993, 21:537-545. 10.1016/0735-1097(93)90700-B, 8426022.
2. Ambrosio G, Tritto II. Lethal Myocardial Reperfusion Injury: Does it Exist, Should We Treat It?. J Thromb Thrombolysis 1997, 4:69-70. 10.1023/A:1017554619252, 10639229.
3. Hearse DJ, Bolli R. Reperfusion induced injury: manifestations, mechanisms, and clinical relevance. Cardiovasc Res 1992, 26:101-108. 10.1093/cvr/26.2.101, 1571929.
4. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974, 54:1496-1508. 10.1172/JCI107898, 301706, 4140198.
5. Bekkers SC, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 55:1649-1660. 10.1016/j.jacc.2009.12.037, 20394867.
6. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998, 97:765-772.
7. Diepenhorst GM, van Gulik TM, Hack CE. Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg 2009, 249:889-899. 10.1097/SLA.0b013e3181a38f45, 19474697.
8. Crawford MH, Grover FL, Kolb WP, McMahan CA, O'Rourke RA, McManus LM, Pinckard RN. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 1988, 78:1449-1458.
9. Pinckard RN, O'Rourke RA, Crawford MH, Grover FS, McManus LM, Ghidoni JJ, Storrs SB, Olson MS. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest 1980, 66:1050-1056. 10.1172/JCI109933, 371542, 7000824.
10. Rossen RD, Michael LH, Kagiyama A, Savage HE, Hanson G, Reisberg MA, Moake JN, Kim SH, Self D, Weakley S. Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human C1q in vivo. Circ Res 1988, 62:572-584.
11. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res 1992, 71:303-319.
12. Weisman HF, Bartow T, Leppo MK, Marsh HC, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990, 249:146-151. 10.1126/science.2371562, 2371562.
13. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002, 105:656-662. 10.1161/hc0502.102867, 11827935.
14. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997, 95:320-323.
15. Fernandez HN, Henson PM, Otani A, Hugli TE. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol 1978, 120:109-115.
16. Amsterdam EA, Pan HL, Rendig SV, Symons JD, Fletcher MP, Longhurst JC. Limitation of myocardial infarct size in pigs with a dual lipoxygenase-cyclooxygenase blocking agent by inhibition of neutrophil activity without reduction of neutrophil migration. J Am Coll Cardiol 1993, 22:1738-1744. 10.1016/0735-1097(93)90605-Z, 8227848.
17. Mehta JL, Nichols WW, Mehta P. Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. J Am Coll Cardiol 1988, 11:1309-1316. 10.1016/0735-1097(88)90297-5, 3284944.
18. Mullane KM, Read N, Salmon JA, Moncada S. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther 1984, 228:510-522.
19. Engler R. Consequences of activation and adenosine-mediated inhibition of granulocytes during myocardial ischemia. Fed Proc 1987, 46:2407-2412.
20. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004, 61:481-497. 10.1016/j.cardiores.2003.10.011, 14962479.
21. Gustafsson E, Rosen A, Barchan K, van Kessel KP, Haraldsson K, Lindman S, Forsberg C, Ljung L, Bryder K, Walse B, et al. Directed evolution of chemotaxis inhibitory protein of Staphylococcus aureus generates biologically functional variants with reduced interaction with human antibodies. Protein Eng Des Sel 2010, 23:91-101. 10.1093/protein/gzp062, 19959567.
22. Gustafsson E, Haas PJ, Walse B, Hijnen M, Furebring C, Ohlin M, van Strijp JA, van Kessel KP. Identification of conformational epitopes for human IgG on Chemotaxis inhibitory protein of Staphylococcus aureus. BMC Immunol 2009, 10:13. 10.1186/1471-2172-10-13, 2662796, 19284584.
23. Gustafsson E, Forsberg C, Haraldsson K, Lindman S, Ljung L, Furebring C. Purification of truncated and mutated Chemotaxis Inhibitory Protein of Staphylococcus aureus--an anti-inflammatory protein. Protein Expr Purif 2009, 63:95-101. 10.1016/j.pep.2008.09.017, 18950716.
24. Gustafsson E. Molecular evolution of a C5aR antagonist against inflammatory disease. PhD Thesis 2009, Lund University, Deparment of Immunotechnology.
25. Smith DA, Jones BC, Walker DK. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 1996, 16:243-266. 10.1002/(SICI)1098-1128(199605)16:3<243::AID-MED2>3.0.CO;2-Z, 8727426.
26. Gotberg M, Olivecrona GK, Engblom H, Ugander M, van der Pals J, Heiberg E, Arheden H, Erlinge D. Rapid short-duration hypothermia with cold saline and endovascular cooling before reperfusion reduces microvascular obstruction and myocardial infarct size. BMC Cardiovasc Disord 2008, 8:7. 10.1186/1471-2261-8-7, 2323360, 18402663.
27. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999, 100:1992-2002.
28. Heiberg E, Ugander M, Engblom H, Gotberg M, Olivecrona GK, Erlinge D, Arheden H. Automated quantification of myocardial infarction from MR images by accounting for partial volume effects: animal, phantom, and human study. Radiology 2008, 246:581-588. 10.1148/radiol.2461062164, 18055873.
29. Heiberg E, Sjogren J, Ugander M, Carlsson M, Engblom H, Arheden H. Design and validation of Segment--freely available software for cardiovascular image analysis. BMC Med Imaging 10:1. 10.1186/1471-2342-10-1, 2822815, 20064248.
30. Ugander M, Heiberg E, Soneson H, Engblom H, van der Pals J, Erlinge D, Arheden H. A novel method for quantifying myocardial perfusion SPECT defect size by co-registration and fusion with MRI - an experimental ex vivo imaging pig heart study. Scand Cardiovasc J 2008, 42(Suppl):47.
31. Wu KC, Kim RJ, Bluemke DA, Rochitte CE, Zerhouni EA, Becker LC, Lima JA. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol 1998, 32:1756-1764. 10.1016/S0735-1097(98)00429-X, 9822106.
32. Schwartz LM, Verbinski SG, Vander Heide RS, Reimer KA. Epicardial temperature is a major predictor of myocardial infarct size in dogs. J Mol Cell Cardiol 1997, 29:1577-1583. 10.1006/jmcc.1997.0391, 9220343.
33. Hedstrom E, Engblom H, Frogner F, Astrom-Olsson K, Ohlin H, Jovinge S, Arheden H. Infarct evolution in man studied in patients with first-time coronary occlusion in comparison to different species - implications for assessment of myocardial salvage. J Cardiovasc Magn Reson 2009, 11:38. 10.1186/1532-429X-11-38, 2758877, 19775428.
34. Dreyer WJ, Michael LH, Nguyen T, Smith CW, Anderson DC, Entman ML, Rossen RD. Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. Circ Res 1992, 71:1518-1524.
35. Martin SE, Chenoweth DE, Engler RL, Roth DM, Longhurst JC. C5a decreases regional coronary blood flow and myocardial function in pigs: implications for a granulocyte mechanism. Circ Res 1988, 63:483-491.
36. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995, 268:H448-457.
37. Tofukuji M, Stahl GL, Agah A, Metais C, Simons M, Sellke FW. Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. J Thorac Cardiovasc Surg 1998, 116:1060-1068. 10.1016/S0022-5223(98)70059-5, 9832699.
38. Riley RD, Sato H, Zhao ZQ, Thourani VH, Jordan JE, Fernandez AX, Ma XL, Hite DR, Rigel DF, Pellas TC, et al. Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization. J Thorac Cardiovasc Surg 2000, 120:350-358. 10.1067/mtc.2000.107281, 10917953.
39. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998, 97:2259-2267.
40. Tanhehco EJ, Lee H, Lucchesi BR. Sublytic complement attack reduces infarct size in rabbit isolated hearts: evidence for C5a-mediated cardioprotection. Immunopharmacology 2000, 49:391-399. 10.1016/S0162-3109(00)00258-7, 10996036.
41. Atar D, Petzelbauer P, Schwitter J, Huber K, Rensing B, Kasprzak JD, Butter C, Grip L, Hansen PR, Suselbeck T, et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009, 53:720-729. 10.1016/j.jacc.2008.12.017, 19232907.
42. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D, O'Neill WW, Todaro TG, Vahanian A, Van de Werf F. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. Jama 2007, 297:43-51. 10.1001/jama.297.17.1881-b, 17200474.
43. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996, 33:1389-1401. 10.1016/S0161-5890(96)00078-8, 9171898.
44. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003, 108:1184-1190. 10.1161/01.CIR.0000087447.12918.85, 12925454.
45. Zhang H, Qin G, Liang G, Li J, Barrington RA, Liu DX. C5aR-mediated myocardial ischemia/reperfusion injury. Biochem Biophys Res Commun 2007, 357:446-452. 10.1016/j.bbrc.2007.03.152, 17416341.
46. Inagaki K, Chen L, Ikeno F, Lee FH, Imahashi K, Bouley DM, Rezaee M, Yock PG, Murphy E, Mochly-Rosen D. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 2003, 108:2304-2307. 10.1161/01.CIR.0000101682.24138.36, 14597593.
47. Ikeno F, Inagaki K, Rezaee M, Mochly-Rosen D. Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage. Cardiovasc Res 2007, 73:699-709. 10.1016/j.cardiores.2006.12.011, 2180159, 17234167.
48. Bates E, Bode C, Costa M, Gibson CM, Granger C, Green C, Grimes K, Harrington R, Huber K, Kleiman N, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008, 117:886-896. 10.1161/CIRCULATIONAHA.107.759167, 18250271.